Building Better Oral Suspensions for Pediatric & Real-World Use - Top-Institutions - MDSpire

Building Better Oral Suspensions for Pediatric & Real-World Use

Greg Thomas, Kiel Laboratories’ Vice President of R&D, discusses oral suspensions, excipients, and patient-centered formulation

  • February 18, 2026

  • 6 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    University of Michigan College of Pharmacy
    University of Michigan College of Pharmacy

    Ann Arbor, MI

    Key Differentiators

    • Pharmaceutical Sciences
    • Pediatric Formulations
    • Drug Delivery

  • #2

    University of North Carolina at Chapel Hill Eshelman School of Pharmacy
    University of North Carolina at Chapel Hill Eshelman School of Pharmacy

    Chapel Hill, NC

    Key Differentiators

    • Pharmaceutical Sciences
    • Pediatric Drug Development
    • Clinical Pharmacology

  • #3

    University of California, San Francisco (UCSF) School of Pharmacy
    University of California, San Francisco (UCSF) School of Pharmacy

    San Francisco, CA

    Key Differentiators

    • Pharmaceutical Sciences
    • Pediatric Pharmacology
    • Drug Formulation

  • #4

    Children's Hospital of Philadelphia (CHOP) Research Institute
    Children's Hospital of Philadelphia (CHOP) Research Institute

    Philadelphia, PA

    Key Differentiators

    • Pediatric Clinical Research
    • Pharmacology
    • Drug Formulation

  • #5

    Massachusetts Institute of Technology (MIT) Department of Chemical Engineering
    Massachusetts Institute of Technology (MIT) Department of Chemical Engineering

    Cambridge, MA

    Key Differentiators

    • Pharmaceutical Engineering
    • Drug Delivery Systems
    • Formulation Science

Original Source(s)

Building Better Oral Suspensions for Pediatric & Real-World Use

  • February 18, 2026

Related Content

Myelodysplastic syndromes complicated by atypical Sweet syndrome: a brief research report

Percutaneous nephrostomy as a marker of clinical vulnerability in non-metastatic muscle-invasive bladder cancer: prognostic and infectious implications

Glioblastoma, IDH-wildtype, with a novel MEF2D-NTRK1 gene fusion: a case report